How is ACE-083 different from ACE-031?

ACE-083 is engineered to stay localized in the muscle it is injected into for focal hypertrophy, while ACE-031 is a systemic circulating ligand trap that affects muscle throughout the body.

Did ACE-083 improve muscle function?

In clinical research it reliably increased muscle volume, but those size gains did not consistently translate into measurable improvements in strength or function.

← All peptides

Muscle Growth

Preclinical

ACE-083

Also known as: ACE-083

ACE-083 is a locally acting follistatin-based fusion protein designed to increase muscle size and strength in the specific muscle into which it is injected.

Mechanism of Action

ACE-083 is a fusion of a modified follistatin domain with an IgG2 Fc region engineered for high local retention at the injection site. It sequesters myostatin (GDF-8), activin, and related TGF-beta ligands within the targeted muscle, blocking ActRIIB-mediated SMAD2/3 signaling. Because it is designed to stay localized rather than circulate systemically, it produces focal muscle hypertrophy in the injected muscle, which was studied for focal neuromuscular diseases.

Half-life: Engineered for prolonged local retention; systemic exposure minimal
Administration Routes: intramuscular
Research Status: Preclinical